IT & Data Management

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

IQVIA, known across the life sciences industry for its clinical research operations, commercial analytics, and health-data expertise, has entered a strategic collaboration with Amazon Web Services (AWS), naming AWS as its Preferred Agentic Cloud Provider. Announced during AWS re:Invent,...

4.4% of all greenhouse gas emissions come from the healthcare industry. The supply line for this industry is very complicated, and every year $35 billion worth of goods are lost. Startups have become strong forces for change, using new...

The Sustainable Development Goals (SDGs) included in the UN 2030 Agenda also address the environmental, social, and economic aspects of development. In this sense, the diagnostic and healthcare industries proceed to convert the SDG Global Data agenda into development...

The pharmaceutical industry is undergoing a profound transformation in how it approaches pricing decisions, market access negotiations, and tender participation through the strategic deployment of artificial intelligence technologies. AI in pharma market access represents a paradigm shift from traditional...

The pharmaceutical manufacturing sector stands on the precipice of a fundamental digital transformation driven by the convergence of Internet of Things technologies, edge computing, artificial intelligence, and advanced analytics platforms. IoT in pharma manufacturing represents far more than simple...

The pharmaceutical and biotechnology industries are experiencing a profound technological revolution driven by CRISPR-Cas9 and emerging gene editing technologies that fundamentally alter how therapeutic agents are developed and manufactured. Gene editing pharma manufacturing represents far more than incremental improvement...